India has strengthened regulatory oversight of GLP-1 medicines, directing authorities to closely monitor their sale, supply, and promotion.
The Central Government has strengthened regulatory oversight of GLP-1 receptor agonist medicines, directing drug regulators across States and Union Territories to closely monitor their sale, supply, and promotion.
The move aims to curb surrogate advertising, misleading awareness campaigns, and the unsupervised use of these prescription medicines as demand for weight-loss drugs continues to grow in India. (1Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain
)
Advertisement
Why Has the Government Tightened Rules on GLP-1 Weight-Loss Drugs?
In a written reply in the Rajya Sabha, Minister of State for Health Anupriya Patel said GLP-1 receptor agonists have been approved only for the treatment of Type 2 diabetes and chronic weight management in adults who meet specific medical criteria.
These medicines can be dispensed only on the prescription of endocrinologists or internal medicine specialists, while some approved indications also permit prescriptions by cardiologists.
To prevent misuse, CDSCO issued an advisory directing manufacturers, importers, and marketing authorization holders to strictly follow approved indications under the Drugs and Cosmetics Act.
The advisory prohibits:
- Surrogate advertisements.
- Indirect promotions.
- Disease-awareness campaigns promoting off-label use.
- Digital marketing that encourages use without medical supervision.
The government has also asked State drug regulators to strengthen monitoring across the entire supply chain, ensuring that the manufacture, import, distribution, and sale of GLP-1 medicines occur only through authorised channels.
Advertisement
How Is India Monitoring the Sale and Promotion of GLP-1 Medicines?
Regulatory surveillance has been intensified following the introduction of multiple generic GLP-1 medicines in India and concerns over their increasing availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.
To enforce compliance, regulators carried out audits and inspections at 49 entities, including:
- Online pharmacy warehouses.
- Wholesalers.
- Retail pharmacies.
- Slimming clinics.
The inspections focused on identifying unauthorized sales, improper prescription practices, and misleading marketing, with notices issued to entities found violating regulatory requirements.
The ministry warned that using GLP-1 medicines without proper medical supervision can lead to serious health risks.
It also stated that regulatory action will continue in the coming months, with violations attracting:
- License cancellations.
- Financial penalties.
- Prosecution under applicable laws.
Advertisement
Can GLP-1 Drugs Alone Solve India’s Obesity Challenge?
GLP-1 medicines such as Semaglutide and Tirzepatide have changed obesity treatment by reducing appetite, slowing stomach emptying, and lowering food intake. (2From Thalis to Portion Control: The GLP-1 Debate in India
)
Studies cited in the report show that people using these medicines consume 16% to 39% fewer calories, often develop healthier food preferences, and reduce purchases of processed and sugary foods.
However, experts caution that these medicines are not a substitute for healthy living. Evidence suggests that stopping treatment without maintaining healthy eating habits and physical activity can result in weight regain.
Other reported concerns include:
- Gastrointestinal side effects.
- Nutritional deficiencies.
- Loss of lean muscle mass.
- The need for adequate
protein intake and strength training during treatment.
India faces a dual burden of obesity, diabetes, and other non-communicable diseases. While GLP-1 medicines could become an important tool for managing obesity, long-term success will depend on combining medication with balanced nutrition, regular exercise, behavioural support, and stronger public health measures, rather than relying on medicines alone.
References:
- Regulatory Surveillance Over Weight Loss Drug (GLP-1) Supply Chain. (https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244252&lang=2®=3)
- Observer Research Foundation. From Thalis to Portion Control: The GLP-1 Debate in India. (https://www.orfonline.org/expert-speak/from-thalis-to-portion-control-the-glp-1-debate-in-india)
Source-Medindia